MedTrace Logo

Evaluate the Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia

NCT03249103 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2022-09-16

Study results available
· View outcomes & findings →

Summary

The primary objective is to determine whether daily dosing with NYX-2925 changes markers of central pain processing in subjects with fibromyalgia by evaluating changes in evoked pain, and visual stimulation, functional magnetic resonance imaging (fMRI), resting state function connectivity magnetic resonance imaging (rs-fcMRI) and proton magnetic resonance spectroscopy (H-MRS) in fibromyalgia subjects on active drug versus placebo.

Conditions

  • Fibromyalgia

Interventions

DRUG

NYX-2925

NYX-2925 is a novel small molecule that modulates the N-methyl-D-aspartate receptor (NMDAR).

DRUG

Placebo oral capsule

Matching placebo capsules.

Sponsors & Collaborators

  • inVentiv Health Clinical

    collaborator OTHER

  • Aptinyx

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-14
Primary Completion
2019-04-18
Completion
2019-04-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03249103 on ClinicalTrials.gov